Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
LumiraDx logo — Transforming community-based healthcare through POC diagnost...

LumiraDx

Transforming community-based healthcare through POC diagnostics & making lab-comparable tests accessible to all

Founded 2014 United Kingdom London, United Kingdom 316 employees IPO Total: $825.47M Health Care, Medical Devices

General Information

Company Name LumiraDx
Founded Year 2014
Location United Kingdom London, United Kingdom +2
Founders / Decision Makers
Team member
Employees 316
Industries Health Care, Medical Devices
Funding Stage IPO
Social

Get notified when LumiraDx moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About LumiraDx

LumiraDx, founded in 2014 and headquartered in the United Kingdom, is making significant strides in the healthcare sector by pioneering point-of-care (POC) diagnostics. The company's slogan, "Transforming community-based healthcare through POC diagnostics & making lab-comparable tests accessible to all," encapsulates its mission.

Recently, Roche Diagnostics acquired LumiraDx's next-generation POC Platform technology, marking a pivotal moment for the company. This acquisition underscores LumiraDx's potential to integrate globally with Roche, a leader in both pharmaceuticals and diagnostics. Roche's established expertise promises to enhance LumiraDx's innovative reach, particularly in areas such as oncology and diabetes management.

LumiraDx last secured a $14.20M grant investment in December 2022 from the Bill & Melinda Gates Foundation, highlighting investor confidence in its scalable solutions. Positioned at the intersection of Health Care and Medical Devices, LumiraDx is poised for growth in community healthcare.

Taxonomy: Point-of-Care Diagnostics, Personalised Healthcare, In Vitro Diagnostics, Tissue-Based Cancer Diagnostics, Diabetes Management, Oncology, Infectious Diseases, Digital Connectivity, Clinical Integration, Population Health Management, Patient-Centered Care, Healthcare Innovation, Diagnostic-Led Care, Interoperability

Services & Products

In vitro diagnostic products
Point of care systems
Digital healthcare solutions
Assay and detection systems
Consulting and product services

Target Customers

Healthcare professionals Research institutions Hospitals and clinics Pharmacies Community outreach programs

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
01 Dec 2022
Post Ipo Convertible •••••• - 01 Mar 2022
Spac Private Placement •••••• 1 •••• •••• 01 Sep 2021
Post Ipo Debt •••••• 2
Investor
•••• •••• 		01 May 2021
Late Vc •••••• - 01 Dec 2020

View All 7 Funding Rounds

LumiraDx Alternatives & Competitors

View All Alternatives
LumiraDx vs
Roche
Roche Switzerland

We advance science so that we all have more time with the people we love. Are you ready to join us?

IPO
108149 employees
Pharmaceutical
Compare LumiraDx vs Roche
LumiraDx vs
Siemens Healthineers
Siemens Healthineers Germany

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.

54173 employees
Manufacturing, Pharmaceutical
Compare LumiraDx vs Siemens Healthineers
LumiraDx vs
Monogram Biosciences
Monogram Biosciences United States

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative pr...

202 employees
Biotechnology, Health Care
Also compare with: LumiraDx vs EKF Diagnostics EKF Diagnostics View all alternatives

FAQ About LumiraDx

Transforming community-based healthcare through POC diagnostics & making lab-comparable tests accessible to all
LumiraDx was founded in 2014.
LumiraDx is headquartered in London, United Kingdom.
LumiraDx operates in the following industries: Health Care, Medical Devices.
LumiraDx has approximately 316 employees.
LumiraDx has completed 7 funding rounds, raising a total of $825.47M. The latest funding stage is IPO.
LumiraDx offers: In vitro diagnostic products, Point of care systems, Digital healthcare solutions, Assay and detection systems, Consulting and product services.
Top alternatives and competitors to LumiraDx include Roche, Siemens Healthineers, Monogram Biosciences, EKF Diagnostics, Getwell Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
LumiraDx and Roche are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors LumiraDx and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy